Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17822246 | 0.98 | MAPT (0.70) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL14712472 | 0.84 | MEN1 (0.68) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL29442842 | 0.83 | KMT2A (0.63) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL1703637 | 0.83 | KMT2A (0.63) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL1979091 | 0.83 | MAPT (0.65) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL712713 | 0.83 | MAPT (0.70) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL4024502 | 0.82 | MAPT (0.55) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL3593783 | 0.81 | MAPT (0.68) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL712415 | 0.81 | MAPT (0.73) | MAPTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL3611556 | 0.81 | MAPT (0.97) | MAPTLMNAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-118084890-A | Isoxazoline-containing pyrazole amide compound as well as preparation method and application thereof | 安徽农业大学 | 2024-05-28 | — | — | CN | disclosed |
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
| US-7098335-B2 | Pyrazolopyrimidine compositions | ICAGEN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050215569-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| US-6833371-B2 | Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell | ICAGEN, INC. | 2004-12-21 | — | — | US | disclosed |
| CN-1066448-C | Amide derivatives | OTSUKA PHARMA CO LTD (JP) | 2001-05-30 | — | — | CN | disclosed |
| CN-1221419-A | Amide derivatives | OTSUKA PHARMA CO LTD (JP) | 1999-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215569-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | MAPT 3256/4885LMNA 3875/4885L3MBTL1 4822/4885 |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | BACE1, APH1A, APP | MAPT 203/4885LMNA 679/4885L3MBTL1 1473/4885 |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MAPT 3135/4885LMNA 792/4885L3MBTL1 1570/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | MAPT 1481/4885LMNA 2879/4885L3MBTL1 3402/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | MAPT 1481/4885LMNA 2879/4885L3MBTL1 3402/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | MAPT 2636/4885LMNA 971/4885L3MBTL1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.